Imipenem
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Imipenem is one of the semisynthetic thienamycins with antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, which is stable to many beta-lactamases and shows a long half-life because of binding to plasma proteins [1].
Penicillin-binding proteins (PBPs) are a kind of membrane proteins, widely existing on the surface of bacteria, which is the main target site of beta-lactam antibiotics.
In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b [2]. The inhibition of PBPs reduces the number of peptidoglycan polymer in the bacterial cell, thus prevent the forming of the bacterial cell wall and lead to cell death [3].
Reference:
[1] Zhanel G G, Wiebe R, Dilay L, et al. Comparative review of the carbapenems [J]. Drugs, 2007, 67(7): 1027-52.
[2] Nicolau D P. Carbapenems: a potent class of antibiotics [J]. Expert Opin Pharmacother. 2008, 9(1): 23-37.
[3] Brunton L L, Hilal-Dandan R, Knollmann B C. eds (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 299.35 |
Cas No. | 64221-86-9 |
Formula | C12H17N3O4S |
Solubility | insoluble in EtOH; insoluble in DMSO; ≥29.9 mg/mL in H2O with gentle warming |
Chemical Name | (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
SDF | Download SDF |
Canonical SMILES | C[C@](O)([H])[C@](C1=O)([H])[C@@](N21)([H])CC(SCCNC=N)=C2C(O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines |
Polymorphonuclear leucocytes (PMNs) and lymphomonocytes |
Reaction Conditions |
15, 30 and 60 mg/l imipenem |
Applications |
Preincubation of PMNs with the highest dosages (30 and 60 mg/l) was found to increase phagocytosis, while no effect was detected on superoxide anion production, as well as on lymphomonocyte proliferative response and cytokine production. |
Animal experiment:[2] | |
Animal models |
Male Sprague-Dawley rats aged 8 ~ 10 weeks and weighing 150 ~ 250 g, subjected to cecal ligation and puncture (CLP) |
Dosage form |
120 mg/kg Injected intraperitoneally 6 h post-CLP and every 12 h for a total of 7 days |
Applications |
Imipenem combined with low-dose cyclophosphamide (CTX) could improve the survival rate of rats with sepsis compared with rats treated with imipenem alone. However, this combination significantly reduced IL-10 expression, potentially causing damage to the intestinal barrier function. |
Note |
The technical data provided above is for reference only. |
References: 1. Pasqui AL, Di Renzo M, Bruni F, et al. Imipenem and immune response: in vitro and in vivo studies. Drugs under Experimental and Clinical Research, 1995, 21(1): 17-22. 2. Guo P, Zhang SW, Zhang J, et al. Effects of imipenem combined with low-dose cyclophosphamide on the intestinal barrier in septic rats. Experimental and Therapeutic Medicine, 2018, 16(3): 1919-1927. |
质量控制和MSDS
- 批次: